Scholarlink

Background <p>Metabolic syndrome (MetS) significantly elevates the risk of diabetes and cardiovascular disease. While insulin resistance (IR) underpins MetS pathogenesis, practical biomarkers for population screening remain limited. The metabolic score for IR (METS-IR), lipid accumulation product (LAP) and visceral adiposity index (VAI) are highly sensitive and specific biomarkers of IR, which require comparative validation.</p> Objective <p>To compare LAP, VAI, and METS-IR index for predicting MetS with sex-stratified analysis.</p> Methods <p>The physiological characteristics and blood biochemistry data collected from 2821 patients during an annual health check-up were analyzed. Participants were assigned to MetS group (≥3 MetS conditions), pre-Mets group (1–2 Mets components) or control group (0 component) based on IDF/AHA/NHLBI 2009 criteria and were further stratified by sex. The predictive value and clinical usefulness of the LAP, VAI, and METS-IR were evaluated by receiver operating characteristic (ROC) curve and decision curve analysis (DCA).</p> Results <p>LAP, VAI, and METS-IR levels were significantly elevated in the MetS group (<i>P</i> &lt; 0.05) and strongly correlated with MetS components. ROC analysis revealed LAP as the superior predictor in the total cohort (AUC: 0.904 [95% CI: 0.888–0.920]) and females (AUC: 0.949 [95% CI: 0.921–0.976]), while VAI performed best in males (AUC: 0.863 [95% CI: 0.840–0.886]). DCA confirmed the superior clinical utility of LAP and VAI over METS-IR across subgroups.</p> Conclusion <p>This large-scale validation establishes LAP and VAI as superior, sex-specific predictors of MetS compared to METS-IR. LAP is optimal overall and in women, while VAI is optimal in men. Their reliance on standard clinical measurements establishes them as practical tools for metabolic risk stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Visceral lipid accumulation and lipid accumulation product outperform insulin resistance score for metabolic syndrome prediction in Northern Chinese adults: validation through AUC comparison and decision curve analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月14日

查看全文
  • Qing Liu,
  • Xing Guan,
  • Li-Jun Wang,
  • Zheng Wang,
  • Han Zhang,
  • Yu-Qiang Zuo

摘要

Background

Metabolic syndrome (MetS) significantly elevates the risk of diabetes and cardiovascular disease. While insulin resistance (IR) underpins MetS pathogenesis, practical biomarkers for population screening remain limited. The metabolic score for IR (METS-IR), lipid accumulation product (LAP) and visceral adiposity index (VAI) are highly sensitive and specific biomarkers of IR, which require comparative validation.

Objective

To compare LAP, VAI, and METS-IR index for predicting MetS with sex-stratified analysis.

Methods

The physiological characteristics and blood biochemistry data collected from 2821 patients during an annual health check-up were analyzed. Participants were assigned to MetS group (≥3 MetS conditions), pre-Mets group (1–2 Mets components) or control group (0 component) based on IDF/AHA/NHLBI 2009 criteria and were further stratified by sex. The predictive value and clinical usefulness of the LAP, VAI, and METS-IR were evaluated by receiver operating characteristic (ROC) curve and decision curve analysis (DCA).

Results

LAP, VAI, and METS-IR levels were significantly elevated in the MetS group (P < 0.05) and strongly correlated with MetS components. ROC analysis revealed LAP as the superior predictor in the total cohort (AUC: 0.904 [95% CI: 0.888–0.920]) and females (AUC: 0.949 [95% CI: 0.921–0.976]), while VAI performed best in males (AUC: 0.863 [95% CI: 0.840–0.886]). DCA confirmed the superior clinical utility of LAP and VAI over METS-IR across subgroups.

Conclusion

This large-scale validation establishes LAP and VAI as superior, sex-specific predictors of MetS compared to METS-IR. LAP is optimal overall and in women, while VAI is optimal in men. Their reliance on standard clinical measurements establishes them as practical tools for metabolic risk stratification.